(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/173598 A1

(51) International Patent Classification:
A61K 31/706 (2006.01) *A61K 31/7068* (2006.01)

(21) International Application Number:
PCT/US2021/019310

(22) International Filing Date:
24 February 2021 (24.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/981,304 25 February 2020 (25.02.2020) US

(71) Applicant: **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 2-9 Kanda Tsukasa-Machi, Chiyoda-Ku, Tokyo 101-8535 (JP).

(72) Inventors: **OGANESIAN, Aram**; 2532 Molinaro Way, Dublin, California 94568 (US). **DAVAR, Nipun**; 868 Piemonte Drive, Pleasanton, California 94566 (US). **KOU, Jim Hwaicher**; 1558 Larkin Avenue, San Jose, California 95129 (US).

(74) Agent: **Schwartzman, Robert A.**; Myers Bigel, P.A., P.O. Box 37428, Raleigh, North Carolina 27627 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS




FIG. 1

(57) Abstract: Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m^2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m^2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.

WO 2021/173598 A1